the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
October 10, 2014 – The European Medicines Agency recently has recommended the authorisation of Harvoni (ledipasvir / sofosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection in adults. HCV infection is a major European public-health challenge. It affects between …
July 10, 2014 – The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has endorsed daclatasvir (Daklinza, Bristol-Myers Squibb) to treat adults with chronic hepatitis C virus (HCV) infection, in combination with other drugs. Daclatasvir is …
EMA: EU Panel Endorses Daclatasvir (Daklinza) for Chronic Hepatitis C Infection Read more »
July 09, 2014 – A very exiting review article in the British Medical Journal (BMJ) on July 07, 2014 discusses the newest developments in the treatment options in HCV infection. This is an excerpt from the article, which can be …
Newest developments in antiviral treatment options in hepatitis C virus infection (HCV) Read more »